Scholarlink

Objective <p>Esophageal squamous cell carcinoma (ESCC) is a lethal malignancy with limited therapeutic options, primarily due to its aggressive metastatic behavior. This study aimed to elucidate the molecular drivers of ESCC metastasis by identifying a critical oncogene and investigate its functional mechanisms.</p> Methods <p>Using integrated bioinformatics screening, we identified NDC80 as a potential regulator of metastasis. The role and underlying mechanisms of NDC80 in ESCC progression have remained to be fully elucidated. We conducted&#xa0;in vitro&#xa0;functional assays—including real-time PCR, western blotting, and flow cytometry—to assess the effects of NDC80 on epithelial-mesenchymal transition (EMT) and malignant behavior. Mechanistic studies such as co-culture systems and ELISA, were used to evaluate tumor-associated macrophages (TAMs) polarization, with a specific focus on the PI3K/AKT pathway. In vivo, we established subcutaneous xenograft models in immunocompromised mice to validate the impact of NDC80 on ESCC progression. Clinical validation was performed using immunohistochemistry analysis of ESCC tissue samples.</p> Results <p>NDC80 was identified as a clinically significant oncogene, showing marked overexpression in ESCC tissues that was associated with advanced invasion depth, lymphatic metastasis, and vascular invasion. Functionally, NDC80 promoted tumor cell migration, invasion, and EMT progression. Mechanistically, NDC80 fostered a tumor-promoting microenvironment by inducing M2 macrophages polarization via secretion of M-CSF and CXCL-2, which in turn activated the PI3K/AKT pathway to further amplify EMT.</p> Conclusion <p>Our findings established NDC80 as a master regulator of ESCC metastasis by activating TAM-mediated PI3K/AKT and promoting EMT. These insights positioned NDC80 as a promising therapeutic target, offering a potential strategy to prevent ESCC progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NDC80 promotes epithelial to mesenchymal transition of esophageal squamous cell carcinoma through macrophages polarization and PI3K/AKT pathway activation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月10日

查看全文
  • Jiao Shu,
  • Chenbo Yang,
  • Zexin Sun,
  • Yinghao Liang,
  • Na Zhao,
  • Xiaonan Liu,
  • Yiwei Li,
  • Muhammad Saud Tabish,
  • Miaomiao Sun,
  • Kuisheng Chen

摘要

Objective

Esophageal squamous cell carcinoma (ESCC) is a lethal malignancy with limited therapeutic options, primarily due to its aggressive metastatic behavior. This study aimed to elucidate the molecular drivers of ESCC metastasis by identifying a critical oncogene and investigate its functional mechanisms.

Methods

Using integrated bioinformatics screening, we identified NDC80 as a potential regulator of metastasis. The role and underlying mechanisms of NDC80 in ESCC progression have remained to be fully elucidated. We conducted in vitro functional assays—including real-time PCR, western blotting, and flow cytometry—to assess the effects of NDC80 on epithelial-mesenchymal transition (EMT) and malignant behavior. Mechanistic studies such as co-culture systems and ELISA, were used to evaluate tumor-associated macrophages (TAMs) polarization, with a specific focus on the PI3K/AKT pathway. In vivo, we established subcutaneous xenograft models in immunocompromised mice to validate the impact of NDC80 on ESCC progression. Clinical validation was performed using immunohistochemistry analysis of ESCC tissue samples.

Results

NDC80 was identified as a clinically significant oncogene, showing marked overexpression in ESCC tissues that was associated with advanced invasion depth, lymphatic metastasis, and vascular invasion. Functionally, NDC80 promoted tumor cell migration, invasion, and EMT progression. Mechanistically, NDC80 fostered a tumor-promoting microenvironment by inducing M2 macrophages polarization via secretion of M-CSF and CXCL-2, which in turn activated the PI3K/AKT pathway to further amplify EMT.

Conclusion

Our findings established NDC80 as a master regulator of ESCC metastasis by activating TAM-mediated PI3K/AKT and promoting EMT. These insights positioned NDC80 as a promising therapeutic target, offering a potential strategy to prevent ESCC progression.